Transgene Completes TG4050 Phase 2 Randomization
Analysis based on 6 articles · First reported Apr 13, 2026 · Last updated Apr 14, 2026
The completion of patient randomization in Transgene's Phase 2 clinical trial for TG4050 is a positive development for the company, potentially increasing investor confidence in its pipeline and future revenue prospects. Positive results from this trial could significantly impact Transgene's stock price and position in the biotechnology sector, especially in cancer immunotherapies.
Transgene announced the completion of patient randomization in the Phase 2 part of its Phase 1/2 clinical trial for TG4050, an individualized neoantigen therapeutic vaccine for head and neck cancer. A total of 38 patients have been randomized, and Transgene expects to release top-line results for the primary endpoint of 2-year disease-free survival by the end of Q1 2028. Dr. Alessandro Riva, Chairman and CEO of Transgene, highlighted this as an important milestone for TG4050 and the myvac® platform. Data from the Phase 1 part of the trial, published in January 2026, showed TG4050 was well-tolerated and induced long-lasting immune responses, with all treated patients disease-free at 2-years. The myvac® platform, developed by Transgene with AI capabilities from Oracle Corporation, aims to create personalized immunotherapies. France — Bpifrance has provided funding for the myvac® platform's development.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard